AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019Pharmacoeconomic evaluation of JULUCA (DTG/RPV) for human immunodeficiency virus (HIV-1) infection treatment in virologically-supressed adults in Taiwan.View Abstract
AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019Weight-based ART regimens in adults can achieve viral suppression and save costsView Abstract
AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019Impact of point-of-care pharmacist counseling at late refills of antiretroviral therapy: A Study Following the Early Warning Indicators of World Health Organization RecommendationsView Abstract
AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019Raltigravir was non-superior to Lopinavir/ritonavir for treatment-experienced Chinese patients with HIV-1 infection: a 48-week randomized multicenter control studyView Abstract
AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019Evolution of weight and lipid profiles in HIV-positive patients switched to coformulated elvitegravir/ cobicistat/emtricitabine/ tenofovir alafenamideView Abstract
AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019Low prevalence of HLA-B*5701 and abacavir intolerance in HLA-B*5701 negative Thais with acute HIV infectionView Abstract
AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019The efficacy and safety of two-drug regimen including dolutegravir plus a boosted protease inhibitor in highly experienced HIV-infected patientsView Abstract
AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019Effectiveness and Tolerability of Switch of Combination Antiretroviral Therapy to Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide among HIV-Positive TaiwaneseView Abstract
AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019Efficacy and Safety of Doravirine in Treatment-Naïve Asian Adults with HIV-1View Abstract
AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019Six-year Immunologic Recovery and Virological Suppression of LPV/r-based Second-line Antiretroviral among HIV Patients: A Multi-center Real-world Cohort Study in ChinaView Abstract
AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019Efficacy of dolutegravir (DTG) plus lamivudine (3TC) versus DTG plus tenofovir/emtricitabine (TDF/FTC) in antiretroviral treatment-naive adults with HIV-1 infection: 48-week subgroup results from the GEMINI studies in participants from Asian centersView Abstract
AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019Predictors of long-term survival in the TREAT Asia HIV Observational Database Low Intensity TransfEr (TAHOD-LITE)View Abstract
